Hereditary nonpolyposis colorectal cancer secondary prevention: Difference between revisions
No edit summary |
|||
(14 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hereditary nonpolyposis colorectal cancer}} | {{Hereditary nonpolyposis colorectal cancer}} | ||
{{CMG}}{{AE}}{{MV}}{{Akram}} | |||
==Overview== | ==Overview== | ||
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy. | [[Secondary prevention]] strategies following hereditary nonpolyposis colorectal cancer include [[genetic testing]], [[colonoscopy]], [[urine]] [[cytology]], [[pelvic exam]], and [[endometrial biopsy]]. | ||
==Secondary prevention== | ==Secondary prevention== | ||
[[Secondary prevention]] strategies following hereditary nonpolyposis colorectal cancer include:<ref name="hnpcc">Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.</ref><ref name="pmid19659756">{{cite journal| author=Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR| title=Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. | journal=Clin Genet | year= 2009 | volume= 76 | issue= 1 | pages= 1-18 | pmid=19659756 | doi=10.1111/j.1399-0004.2009.01230.x | pmc=2846640 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19659756 }} </ref><ref name="pmid8612988">{{cite journal| author=Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G et al.| title=Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. | journal=Gastroenterology | year= 1996 | volume= 110 | issue= 4 | pages= 1020-7 | pmid=8612988 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8612988 }} </ref> | |||
* Colonoscopy 25-35 | * [[Colonoscopy|Colonoscopic]] screening every 2 years from the age of 25 - 35 | ||
* Pelvic exam, transvaginal ultrasound and CA-125 25-35 | * Annual [[Pelvic exam]], [[transvaginal ultrasound]] and [[CA-125]] level [[Test|testing]] from the age of 25 - 35 | ||
* Endometrial biopsy | * [[Endometrial biopsy]] (if warranted clinical [[Symptom|symptoms]]) | ||
* Urine cytology - | * Annual [[Urine]] [[cytology]] from the age of 25 - 35 (for patients who have a family member diagnosed with [[transitional cell carcinoma]] of the [[ureter]] or [[renal pelvis]]) | ||
==References== | ==References== | ||
Line 23: | Line 24: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] |
Latest revision as of 18:17, 7 May 2019
Hereditary Nonpolyposis Colorectal Cancer Microchapters |
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hereditary nonpolyposis colorectal cancer secondary prevention On the Web |
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer secondary prevention |
FDA on Hereditary nonpolyposis colorectal cancer secondary prevention |
CDC on Hereditary nonpolyposis colorectal cancer secondary prevention |
Hereditary nonpolyposis colorectal cancer secondary prevention in the news |
Blogs on Hereditary nonpolyposis colorectal cancer secondary prevention |
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer |
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]Ali Akram, M.B.B.S.[3]
Overview
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam, and endometrial biopsy.
Secondary prevention
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:[1][2][3]
- Colonoscopic screening every 2 years from the age of 25 - 35
- Annual Pelvic exam, transvaginal ultrasound and CA-125 level testing from the age of 25 - 35
- Endometrial biopsy (if warranted clinical symptoms)
- Annual Urine cytology from the age of 25 - 35 (for patients who have a family member diagnosed with transitional cell carcinoma of the ureter or renal pelvis)
References
- ↑ Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.
- ↑ Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009). "Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications". Clin Genet. 76 (1): 1–18. doi:10.1111/j.1399-0004.2009.01230.x. PMC 2846640. PMID 19659756.
- ↑ Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G; et al. (1996). "Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis". Gastroenterology. 110 (4): 1020–7. PMID 8612988.